Jia XH, Xu H, Geng LY, et al. - For resectable nonsmall cell lung cancer (NSCLC), researchers determined the effectiveness as well as the safety of neoadjuvant immunotherapy by analyzing relevant original articles from PubMed, Embase and Cochrane Library that were published prior to January 2020. Overall seven studies with 252 patients were analyzed. Effectiveness was ascertained through major pathological response (MPR) and pathological complete response (pCR). The values in neoadjuvant immunotherapy were shown to be significantly higher vs neoadjuvant chemotherapy, which showed less than 25% MPR and about 2%-15% pCR. For the incidence of treatment-related adverse events, incidence of surgical complications and surgical delay rate, the pooled odds ratio values were estimated to be 0.19, 0.41 and 0.03, respectively; these were significantly better vs neoadjuvant chemotherapy. Overall, as a treatment option for resectable NSCLC, findings showed the effectiveness and the safety of neoadjuvant immunotherapy .